Therapeutic Kinase Inhibitors

Nonfiction, Health & Well Being, Medical, Specialties, Oncology
Cover of the book Therapeutic Kinase Inhibitors by , Springer Berlin Heidelberg
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783642282966
Publisher: Springer Berlin Heidelberg Publication: November 27, 2012
Imprint: Springer Language: English
Author:
ISBN: 9783642282966
Publisher: Springer Berlin Heidelberg
Publication: November 27, 2012
Imprint: Springer
Language: English

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.

More books from Springer Berlin Heidelberg

Cover of the book How Interval and Fuzzy Techniques Can Improve Teaching by
Cover of the book The Pathophysiology of Pneumoperitoneum by
Cover of the book Leukemias by
Cover of the book Mathematik kompakt by
Cover of the book Ein Gedächtnis wie ein Elefant? by
Cover of the book Transcultural Turbulences by
Cover of the book Neonatal Intensive Care by
Cover of the book Human Resource Management by
Cover of the book Oral Candidosis by
Cover of the book Atomic Processes in Basic and Applied Physics by
Cover of the book Statistical Models for Proportions and Probabilities by
Cover of the book Star Clusters in the Era of Large Surveys by
Cover of the book Population Ageing - A Threat to the Welfare State? by
Cover of the book Thermoregulation of Sick and Low Birth Weight Neonates by
Cover of the book Organ-Selective Actions of Steroid Hormones by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy